Stalevo clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses Stalevo is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Stalevo
- 4
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Orion Corporation, Orion Pharma (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Asan Medical Center (1)
Studies
Open first, then newest update. How each study uses Stalevo is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clinical Study of Stalevo in the Treatment of Early Parkinson's DiseaseStatus unknownPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04952194Written as Stalevo
- Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's DiseaseStatus unknownNot applicableAsan Medical CenterNCT02452606Written as Stalevo®
- Study to Evaluate Initiation of Stalevo in Early Wearing-offCompletedPhase 4Orion Corporation, Orion PharmaNCT00462007Written as Stalevo
- Levodopa Concentration Profile With Stalevo 75/125 mgCompletedPhase 1Orion Corporation, Orion PharmaNCT01070628Written as Stalevo (levodopa/ carbidopa/ entacapone)
- Stalevo in Early Wearing-Off PatientsCompletedPhase 4Orion Corporation, Orion PharmaNCT00125567Written as Stalevo (levodopa/carbidopa/entacapone)
As the comparator · 2 — what is tested is compared with Stalevo
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)CompletedPhase 2Orion Corporation, Orion PharmaNCT02764125Written as Stalevo
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsCompletedPhase 2Orion Corporation, Orion PharmaNCT01766258Written as Stalevo